Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey. Show more

110 Allen Road, Basking Ridge, NJ, 07920, United States

https://www.lisata.com

Biotechnology

Healthcare

Start AI Chat

Market Cap

45.34M

52 Wk Range

$1.81 - $5.07

Previous Close

$5.01

Open

$5.01

Volume

15,337

Day Range

$5.01 - $5.03

Enterprise Value

23.33M

Cash

15.96M

Avg Qtr Burn

-3.249M

Insider Ownership

19.21%

Institutional Own.

7.86%

Qtr Updated

12/31/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
LSTA12 (HONEDRA®) Details Critical limb ischemia	Phase 3 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Certepetide (LSTA1) Details Pancreatic cancer	Phase 2b Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + temozolomide Details Cancer, Glioblastoma, Glioma	Phase 2a Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + Standard of care Details Cholangiocarcinoma	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + FOLFIRINOX (neoadjuvant) + panitumumab Details Pancreatic cancer, Colorectal cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + gemcitabine/nab-paclitaxel Details Pancreatic cancer	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + Durvalumab/gemcitabine/nab-paclitaxel Details Pancreatic cancer	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA1 + nivolumab/FOLFIRINOX, Details Cancer, Gastroesophageal adenocarcinomas	Phase 1/2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Gemcitabine/nab-paclitaxel + continuous infusion of certepetide/placebo Details Pancreatic cancer, Cancer	Phase 1/2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
OLOGO (CLBS14) Details Angina	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
LSTA201 (CLBS201) Details Chronic kidney disease	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
XOWNA (CLBS16) Details Coronary Microvascular Dysfunction	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.